1Yoneda T.Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone[J].Eur J Cancer,1998,34(2):240-245.
2Wikenheisex KA,Silberstein EB.Bone scintigraphy screening in stage Ⅱ-Ⅲ breast cancer,is it cost effective?[J].Cleve Clin J Med,1996,63:4347.
3Coleman RE.Monitoring of bone metastases[J].Eur J Cancer,1998,34;252-259.
4Seyedin SM,Roben DM.Matrix proteins of the skeleton[J].Curr Opin Cell Bio,1990,2 ; 914-919.
5Berfolini DR,Nedwin GE,Bringman TS,et al.Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors[J].Nature,4986,319:516-518.
6Uebelhart D,Schlemmer A,Johansen JS,et al.Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links[J].J Clin Endoerinol Metab,1991,72:367-373.
7Wymenga LF,Groenier K,Schuurman J,et al.Pretreat-ett levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis[J].BJU Int,2001,88(3):231-235.
8Ming FH,Shwu BL,Shyng S,et al.Diagnostic value of urine deoxypyridinoline for detecting bone metastases in breast cancer patients[J].Annals of Clinical and Laboratory Science,2003,33 (1):55.61.
9Nguyen-Pamart M,Bonneterre J,Hecxlud B.Urinary excretion of deoxypyndinolme in patients with breast cancer[J].Anticancer Res,1995,15:1601-1604.
